Compounded GLP-1s and the Additive Problem: What a Tirzepatide-B12 Impurity Study Means for Research Quality Standards

Key takeaways

• A peer-reviewed paper published in Expert Opinion on Drug Safety (April 2026) identified a novel, previously unknown impurity in mass-compounded tirzepatide products blended with vitamin B12, formed by a direct chemical reaction between the two substances.
• The FDA has proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — a step that, if finalised, would foreclose any future compounding pathway regardless of shortage status.
• As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide, many involving dosing errors.
• The episode highlights a broader analytical chemistry principle relevant to all peptide research procurement: complex peptide molecules can react with co-formulants in ways that are not detected without targeted analytical testing.

Background: why compounders added B12 in the first place

When tirzepatide (Mounjaro, Zepbound) came off the FDA's official drug shortage list in December 2024 and semaglutide followed in February 2025, the legal pathway that had allowed compounding pharmacies to produce copies of these drugs was eliminated. Faced with narrowing regulatory space, many compounders sought to differentiate their products by adding supplementary ingredients. To differentiate their products from the FDA-approved GLP-1s, many compounders added extra ingredients — most commonly vitamin B12, but also B6, niacinamide, glycine, or carnitine — that have no proven benefit for weight loss or diabetes management.

The commercial logic was straightforward: a product formulated with a named co-ingredient could arguably be characterised as a distinct compounded preparation rather than a copy of the approved drug. The scientific logic, however, was not tested.

The impurity finding

A study published in Expert Opinion on Drug Safety (Jordan et al., 2026 May;25(5):837–845) examined samples of compounded tirzepatide combined with B12 obtained from multiple sources in the US market. Compounded versions of tirzepatide are widely available in the US in the form of fixed-dose combinations of tirzepatide and various analogues of vitamin B12, mass-marketed as comparable to FDA-approved tirzepatide products even though they undergo no evaluation of their potency or impurity profiles.

The study's principal finding was that a novel impurity — previously unidentified in any characterisation of FDA-approved tirzepatide — was present at substantial levels across multiple compounded samples. The impurity resulted from a chemical reaction between the two compounded substances. The study concluded that the identification of a widespread impurity adds to the existing quality concerns presented by compounded tirzepatide, and underscores the importance of testing and FDA approval before new drugs are marketed.

Eli Lilly replicated the analysis and issued an open letter to healthcare providers in March 2026. Nothing is known about the impurity's short- or long-term effects in humans, its impact on how tirzepatide interacts with GLP-1 and GIP receptors, its toxicity, or how it is processed by the body. Because compounders making these combination drugs are not required to monitor or report adverse events, no post-market safety signal is available.

The Obesity Society described the addition of vitamins and minerals under the guise of personalisation as not only a sham, but potentially harmful when ingredients interact and form byproducts that are not tested for safety.

Regulatory context: the 503B Bulks List proposal

The impurity finding arrived as the FDA's enforcement posture was already tightening substantially. On 30 April 2026, the FDA took the more sweeping step of proposing to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — the list of ingredients that large-scale compounding facilities are legally permitted to use. If that change is finalised, which could take several months, it would close the last legal pathway for most compounded GLP-1s.

The proposed exclusion rests on two statutory conditions that neither semaglutide nor tirzepatide can satisfy: neither is difficult to compound, and neither is necessary for patient care in a way that the approved product does not already meet. The public comment period closed on 29 June 2026, and a final rule is expected later in 2026 or early 2027, according to Pharmacy Times.

As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials — some of which required hospitalisation. The impurity data adds a distinct category of concern: not errors in dose or administration, but unexpected molecular transformation of the active pharmaceutical ingredient itself.

The analytical chemistry lesson for research procurement

The episode carries a principle that extends well beyond the clinical GLP-1 context: peptide molecules are not inert when combined with other substances. Tirzepatide is a 39-amino acid dual GIP/GLP-1 receptor agonist — a relatively large, structurally complex peptide with multiple sites at which electrophilic or nucleophilic co-formulants can react. B12 analogues (cyanocobalamin, methylcobalamin, hydroxocobalamin) are themselves chemically reactive species. The formation of a covalent adduct under aqueous storage conditions is, in retrospect, chemically predictable — but it was not predicted, and it was not tested until a third party identified the impurity analytically.

For UK laboratory procurement teams working with research-grade peptides, the parallel questions are:

What co-formulants are present in your peptide vials? Many commercial research peptide suppliers include excipients — mannitol, acetic acid, DMSO, bacteriostatic water — that may interact with the active compound. Certificate of Analysis (CoA) documents typically confirm peptide identity and purity by HPLC at the point of manufacture, but may not capture changes arising from co-formulants or storage conditions.

Are impurity profiles confirmed by orthogonal methods? HPLC purity figures alone do not detect all impurities. Mass spectrometry — ideally liquid chromatography-mass spectrometry (LC-MS) — is required to detect adducts, degradation products, or unexpected molecular species. Some compounders use chemically distinct structures known as salt forms, such as semaglutide sodium, which is a version of the drug that has a sodium salt attached — a modification whose impact on efficacy can differ from the approved form. Salt-form discrepancies and adduct formation are both issues that HPLC purity percentages will not surface.

Is lot-to-lot consistency tracked? Impurity formation can be batch-dependent, varying with pH, temperature history, co-formulant concentration, and storage duration. A CoA from one lot provides no guarantee about the next, particularly if the manufacturer's process or excipient sourcing changes between batches.

Broader market context

The commercial GLP-1 market continues to consolidate around approved, manufacturer-direct supply. In Q1 2026, Lilly posted 56% year-on-year revenue growth, driven primarily by Mounjaro and Zepbound, and the company is scheduled to report Q2 2026 results on 5 August 2026 — the day after this briefing. Separately, Foundayo (orforglipron), Lilly's once-daily oral small-molecule GLP-1 receptor agonist, was approved on 1 April 2026 and launched through LillyDirect and US retail pharmacies from early April. As a small molecule rather than a peptide, orforglipron does not carry the same compounding risk profile and requires no refrigeration.

The net effect of the impurity findings, the proposed 503B exclusion, and the arrival of an oral non-peptide GLP-1 option is likely to accelerate the structural separation of the clinical GLP-1 market from any residual compounding activity — a trajectory that research procurement teams should monitor closely as it affects both pricing and the regulatory visibility of peptide supply chains more broadly.

What to watch

• FDA final rule on 503B Bulks List exclusion for semaglutide, tirzepatide, and liraglutide — expected before end of 2026.
• Lilly Q2 2026 earnings (5 August 2026): first quarter to include meaningful Foundayo prescription data; management commentary on oral GLP-1 channel dynamics will be closely watched.
• Further analytical studies of other compounded peptide/additive combinations — the tirzepatide-B12 study establishes a methodological template that independent researchers or regulators may apply to other frequently blended peptides in the research and clinical compounding space.